{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:03Z","timestamp":1793747043746,"version":"4.6.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Long noncoding RNAs (lncRNAs) are widely involved in cancer development and progression, but the functions of most lncRNAs have not yet been elucidated. Metastasis is the main factor restricting the therapeutic outcomes of various cancer types, including oral squamous cell carcinoma (OSCC). Therefore, exploring the key lncRNAs that regulate OSCC metastasis and elucidating their molecular mechanisms will facilitate the development of new strategies for effective OSCC therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed the lncRNA expression profiles of tumor tissues from OSCC patients with and without cervical lymph node metastasis, and OSCC cell lines. We revealed high expression of oral squamous cell carcinoma metastasis-related lncRNA 1 (lncOCMRL1) in OSCC patient tumor tissues with lymph node metastasis and highly metastatic OSCC cell lines. The effects of lncOCMRL1 knockdown on the invasion, migration and proliferation abilities of OSCC cells were explored through qRT-PCR, Transwell, colony formation, and cell proliferation experiments. The mechanism by which lncOCMRL1 promotes OSCC metastasis and proliferation was explored through RNA pull-down, silver staining, mass spectrometry, RIP, and WB experiments. To increase its translational potential, we developed a reduction-responsive nanodelivery system to deliver siRNA for antitumor therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We determined that lncOCMRL1 is highly expressed in OSCC metastatic tumor tissues and cells. Functional studies have shown that high lncOCMRL1 expression can promote the growth and metastasis of OSCC cells both in vivo and in vitro. Mechanistically, lncOCMRL1 could induce epithelial-mesenchymal transition (EMT) via the suppression of RRM2 ubiquitination and thereby promote the proliferation, invasion, and migration of OSCC cells. We further constructed reduction-responsive nanoparticles (NPs) for the systemic delivery of siRNAs targeting lncOCMRL1 and demonstrated their high efficacy in silencing lncOCMRL1 expression in vivo and significantly inhibited OSCC tumor growth and metastasis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results suggest that lncOCMRL1 is a reliable target for blocking lymph node metastasis in OSCC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-024-03190-w","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T02:01:44Z","timestamp":1727661704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["LncOCMRL1 promotes oral squamous cell carcinoma growth and metastasis via the RRM2\/EMT pathway"],"prefix":"10.1186","volume":"43","author":[{"given":"Nan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuepeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7508-9236","authenticated-orcid":false,"given":"Zixian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiquan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoding","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"issue":"9625","key":"3190_CR1","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(08)60728-X","volume":"371","author":"A Argiris","year":"2008","unstructured":"Argiris A, et al. Head and neck cancer. Lancet. 2008;371(9625):1695\u2013709.","journal-title":"Lancet"},{"issue":"5","key":"3190_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrc.2018.11","volume":"18","author":"CR Leemans","year":"2018","unstructured":"Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18(5):269\u201382.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3190_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"2","key":"3190_CR4","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/hed.26499","volume":"43","author":"I Arun","year":"2021","unstructured":"Arun I, et al. Lymph node characteristics and their prognostic significance in oral squamous cell carcinoma. Head Neck. 2021;43(2):520\u201333.","journal-title":"Head Neck"},{"issue":"4\u20135","key":"3190_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.oraloncology.2008.06.002","volume":"45","author":"S Warnakulasuriya","year":"2009","unstructured":"Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45(4\u20135):309\u201316.","journal-title":"Oral Oncol"},{"issue":"6","key":"3190_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"3190_CR7","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nrc1370","volume":"4","author":"K Pantel","year":"2004","unstructured":"Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004;4(6):448\u201356.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3190_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cell.2018.01.011","volume":"172","author":"F Kopp","year":"2018","unstructured":"Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172(3):393\u2013407.","journal-title":"Cell"},{"issue":"7","key":"3190_CR9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41568-021-00353-1","volume":"21","author":"SJ Liu","year":"2021","unstructured":"Liu SJ, et al. Long noncoding RNAs in cancer metastasis. Nat Rev Cancer. 2021;21(7):446\u201360.","journal-title":"Nat Rev Cancer"},{"key":"3190_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.canlet.2020.04.014","volume":"483","author":"P-H Peng","year":"2020","unstructured":"Peng P-H, et al. Hypoxia-induced lncRNA RP11-390F4.3 promotes epithelial-mesenchymal transition (EMT) and metastasis through upregulating EMT regulators. Cancer Lett. 2020;483:35\u201345.","journal-title":"Cancer Lett"},{"issue":"3","key":"3190_CR11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ccell.2015.02.004","volume":"27","author":"B Liu","year":"2015","unstructured":"Liu B, et al. A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015;27(3):370\u201381.","journal-title":"Cancer Cell"},{"issue":"7291","key":"3190_CR12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08975","volume":"464","author":"RA Gupta","year":"2010","unstructured":"Gupta RA, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071\u20136.","journal-title":"Nature"},{"issue":"12","key":"3190_CR13","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.cmet.2021.11.011","volume":"33","author":"MK Park","year":"2021","unstructured":"Park MK, et al. NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis. Cell Metabol. 2021;33(12):2380\u2013e23979.","journal-title":"Cell Metabol"},{"issue":"15","key":"3190_CR14","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/0008-5472.CAN-16-2634","volume":"77","author":"A Bhan","year":"2017","unstructured":"Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and Cancer: a New Paradigm. Cancer Res. 2017;77(15):3965\u201381.","journal-title":"Cancer Res"},{"issue":"4","key":"3190_CR15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1152\/physrev.00041.2015","volume":"96","author":"J Beermann","year":"2016","unstructured":"Beermann J, et al. Non-coding RNAs in Development and Disease: background, mechanisms, and therapeutic approaches. Physiol Rev. 2016;96(4):1297\u2013325.","journal-title":"Physiol Rev"},{"issue":"5992","key":"3190_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1126\/science.1192002","volume":"329","author":"MC Tsai","year":"2010","unstructured":"Tsai MC, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329(5992):689\u201393.","journal-title":"Science"},{"key":"3190_CR17","doi-asserted-by":"publisher","first-page":"114113","DOI":"10.1016\/j.addr.2022.114113","volume":"182","author":"G Kara","year":"2022","unstructured":"Kara G, Calin GA, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022;182:114113.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"3190_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrm.2017.104","volume":"19","author":"JD Ransohoff","year":"2018","unstructured":"Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19(3):143\u201357.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"3190_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrg.2015.10","volume":"17","author":"JJ Quinn","year":"2016","unstructured":"Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47\u201362.","journal-title":"Nat Rev Genet"},{"key":"3190_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.semcancer.2021.03.007","volume":"75","author":"L Li","year":"2021","unstructured":"Li L, et al. Multidimensional crosstalk between RNA-binding proteins and noncoding RNAs in cancer biology. Semin Cancer Biol. 2021;75:84\u201396.","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"3190_CR21","doi-asserted-by":"publisher","first-page":"111396","DOI":"10.1016\/j.celrep.2022.111396","volume":"40","author":"L Granieri","year":"2022","unstructured":"Granieri L, et al. Targeting the USP7\/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC\/LSD1 inhibitors. Cell Rep. 2022;40(12):111396.","journal-title":"Cell Rep"},{"issue":"8","key":"3190_CR22","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1016\/j.apsb.2022.12.004","volume":"13","author":"K Yang","year":"2023","unstructured":"Yang K, et al. Nanoparticles (NPs)-mediated lncBCMA silencing to promote eEF1A1 ubiquitination and suppress breast cancer growth and metastasis. Acta Pharm Sin B. 2023;13(8):3489\u2013502.","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"3190_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41418-020-00708-5","volume":"28","author":"PE Cockram","year":"2021","unstructured":"Cockram PE, et al. Ubiquitination in the regulation of inflammatory cell death and cancer. Cell Death Differ. 2021;28(2):591\u2013605.","journal-title":"Cell Death Differ"},{"issue":"2","key":"3190_CR24","doi-asserted-by":"publisher","first-page":"12800","DOI":"10.1080\/21655979.2021.2001241","volume":"12","author":"M Yang","year":"2021","unstructured":"Yang M, et al. Ribonucleotide reductase subunit M2 promotes proliferation and epithelial-mesenchymal transition via the JAK2\/STAT3 signaling pathway in retinoblastoma. Bioengineered. 2021;12(2):12800\u201311.","journal-title":"Bioengineered"},{"issue":"6","key":"3190_CR25","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/ncb2976","volume":"16","author":"A Puisieux","year":"2014","unstructured":"Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014;16(6):488\u201394.","journal-title":"Nat Cell Biol"},{"issue":"11","key":"3190_CR26","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/nm.3336","volume":"19","author":"WL Tam","year":"2013","unstructured":"Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 2013;19(11):1438\u201349.","journal-title":"Nat Med"},{"issue":"1","key":"3190_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-016-0530-6","volume":"15","author":"N Bartonicek","year":"2016","unstructured":"Bartonicek N, Maag JL, Dinger ME. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer. 2016;15(1):43.","journal-title":"Mol Cancer"},{"key":"3190_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.phrs.2016.05.018","volume":"110","author":"G Lavorgna","year":"2016","unstructured":"Lavorgna G, et al. Long non-coding RNAs as novel therapeutic targets in cancer. Pharmacol Res. 2016;110:131\u20138.","journal-title":"Pharmacol Res"},{"key":"3190_CR29","doi-asserted-by":"publisher","first-page":"119760","DOI":"10.1016\/j.biomaterials.2020.119760","volume":"234","author":"S Li","year":"2020","unstructured":"Li S, et al. Redox-responsive polyprodrug nanoparticles for targeted siRNA delivery and synergistic liver cancer therapy. Biomaterials. 2020;234:119760.","journal-title":"Biomaterials"},{"issue":"19","key":"3190_CR30","doi-asserted-by":"publisher","first-page":"e2207118","DOI":"10.1002\/advs.202207118","volume":"10","author":"S Li","year":"2023","unstructured":"Li S, et al. Remodeling serine synthesis and metabolism via nanoparticles (NPs)-Mediated CFL1 silencing to enhance the sensitivity of Hepatocellular Carcinoma to Sorafenib. Adv Sci (Weinh). 2023;10(19):e2207118.","journal-title":"Adv Sci (Weinh)"},{"key":"3190_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.oraloncology.2019.02.001","volume":"90","author":"DK Zanoni","year":"2019","unstructured":"Zanoni DK, et al. Survival outcomes after treatment of cancer of the oral cavity (1985\u20132015). Oral Oncol. 2019;90:115\u201321.","journal-title":"Oral Oncol"},{"issue":"2","key":"3190_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","volume":"147","author":"S Valastyan","year":"2011","unstructured":"Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275\u201392.","journal-title":"Cell"},{"issue":"3","key":"3190_CR33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C. EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2019;29(3):212\u201326.","journal-title":"Trends Cell Biol"},{"issue":"3","key":"3190_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3190_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-pathol-020117-043854","volume":"13","author":"V Mittal","year":"2018","unstructured":"Mittal V. Epithelial mesenchymal transition in Tumor Metastasis. Annu Rev Pathol. 2018;13:395\u2013412.","journal-title":"Annu Rev Pathol"},{"issue":"13","key":"3190_CR36","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1158\/0008-5472.CAN-05-4462","volume":"66","author":"A Gautam","year":"2006","unstructured":"Gautam A, Bepler G. Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res. 2006;66(13):6497\u2013502.","journal-title":"Cancer Res"},{"issue":"1","key":"3190_CR37","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s13046-023-02911-x","volume":"42","author":"LH Giang","year":"2023","unstructured":"Giang LH, et al. Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor. J Exp Clin Cancer Res. 2023;42(1):346.","journal-title":"J Exp Clin Cancer Res"},{"key":"3190_CR38","doi-asserted-by":"publisher","first-page":"110996","DOI":"10.1016\/j.biopha.2020.110996","volume":"133","author":"Y Zhan","year":"2021","unstructured":"Zhan Y, et al. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy. Biomed Pharmacother. 2021;133:110996.","journal-title":"Biomed Pharmacother"},{"issue":"14","key":"3190_CR39","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1158\/1078-0432.CCR-18-4046","volume":"25","author":"YZ Mazzu","year":"2019","unstructured":"Mazzu YZ, et al. A novel mechanism driving poor-prognosis prostate Cancer: overexpression of the DNA repair gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res. 2019;25(14):4480\u201392.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3190_CR40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle M, et al. Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov. 2021;20(8):629\u201351.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"3190_CR41","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmat3765","volume":"12","author":"R Kanasty","year":"2013","unstructured":"Kanasty R, et al. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967\u201377.","journal-title":"Nat Mater"},{"issue":"1","key":"3190_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, et al. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20\u201337.","journal-title":"Nat Rev Cancer"},{"issue":"41","key":"3190_CR43","doi-asserted-by":"publisher","first-page":"e1802565","DOI":"10.1002\/smll.201802565","volume":"14","author":"X Xu","year":"2018","unstructured":"Xu X, et al. Redox-Responsive nanoparticle-mediated systemic RNAi for Effective Cancer Therapy. Small. 2018;14(41):e1802565.","journal-title":"Small"},{"issue":"25","key":"3190_CR44","doi-asserted-by":"publisher","first-page":"7091","DOI":"10.1002\/anie.201601273","volume":"55","author":"X Xu","year":"2016","unstructured":"Xu X, et al. Ultra-pH\u2010Responsive and Tumor\u2010Penetrating Nanoplatform for targeted siRNA delivery with robust anti\u2010Cancer efficacy. Angew Chem Int Ed. 2016;55(25):7091\u20134.","journal-title":"Angew Chem Int Ed"},{"issue":"3","key":"3190_CR45","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1021\/acsnano.6b07195","volume":"11","author":"X Xu","year":"2017","unstructured":"Xu X, et al. Multifunctional envelope-type siRNA delivery nanoparticle platform for prostate Cancer therapy. ACS Nano. 2017;11(3):2618\u201327.","journal-title":"ACS Nano"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03190-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-03190-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03190-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T03:23:32Z","timestamp":1727666612000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-03190-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3190"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-03190-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"30 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted in accordance with international guidelines and the ethical standards outlined in the Declaration of Helsinki. This study was approved by the Sun Yat-sen Memorial Hospital Institutional Review Board. All animal experiments were conducted following the Ministry of Health national guidelines for the housing and care of laboratory animals and were performed in accordance with institutional regulations after review and approval by the Institutional Animal Care and Use Committee at Sun Yat-sen University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}